Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHGCY Chugai Pharmaceutical	$21.28 +2.4%	$24.19	$19.50 ▼ $31.26	$68.42B	0.65	202,089 shs	162,675 shs
DSNKY Daiichi Sankyo	$25.11 +2.9%	$23.76	$20.92 ▼ $42.48	$46.24B	N/A	219,911 shs	141,859 shs
SDZNY Sandoz Group	$59.32 +1.2%	$55.97	$35.61 ▼ $62.86	$25.79B	0.6	22,873 shs	15,085 shs
ZTS Zoetis	$154.15 +0.7%	$154.94	$139.70 ▼ $200.33	$67.83B	0.88	3.73 million shs	3.71 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHGCY Chugai Pharmaceutical	+2.36%	+3.45%	-7.27%	-17.65%	-0.98%
DSNKY Daiichi Sankyo	+2.87%	+2.91%	+7.58%	+3.42%	-35.94%
SDZNY Sandoz Group	+1.21%	+0.99%	+4.90%	+26.73%	+36.78%
ZTS Zoetis	+0.65%	+4.62%	+1.78%	-5.45%	-15.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHGCY Chugai Pharmaceutical	1.5768 of 5 stars	0.0	3.0	2.5	0.0	1.0	0.0	1.9
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SDZNY Sandoz Group	2.7827 of 5 stars	0.0	5.0	0.8	0.0	2.5	0.0	2.5
ZTS Zoetis	4.9198 of 5 stars	3.3	5.0	4.2	0.4	4.0	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHGCY Chugai Pharmaceutical	0.00	N/A	N/A	N/A
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
SDZNY Sandoz Group	2.00	Hold	N/A	N/A
ZTS Zoetis	2.50	Moderate Buy	$202.43	31.32% Upside

Current Analyst Ratings Breakdown

Latest SDZNY, CHGCY, ZTS, and DSNKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$210.00 ➝ $215.00
8/8/2025	SDZNY Sandoz Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHGCY Chugai Pharmaceutical	$7.74B	9.05	$0.86 per share	24.69	$4.16 per share	5.12
DSNKY Daiichi Sankyo	$12.39B	3.84	$1.29 per share	19.45	$5.61 per share	4.48
SDZNY Sandoz Group	$10.36B	2.52	$2.70 per share	21.93	$18.56 per share	3.20
ZTS Zoetis	$9.26B	7.38	$7.12 per share	21.65	$11.23 per share	13.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHGCY Chugai Pharmaceutical	$2.56B	$0.79	26.94	27.28	N/A	33.08%	20.80%	18.17%	10/24/2025 (Estimated)
DSNKY Daiichi Sankyo	$1.95B	$1.03	24.38	23.04	1.20	15.65%	17.92%	8.61%	10/30/2025 (Estimated)
SDZNY Sandoz Group	$1M	N/A	0.00	17.87	0.99	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.49B	$5.81	26.53	22.84	2.46	27.83%	56.90%	19.54%	11/3/2025 (Estimated)

Latest SDZNY, CHGCY, ZTS, and DSNKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	ZTS Zoetis	$1.62	$1.76	+$0.14	$1.61	$2.41 billion	$2.46 billion
7/24/2025	Q2 2025	CHGCY Chugai Pharmaceutical	N/A	$0.20	N/A	$0.20	N/A	$2.01 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHGCY Chugai Pharmaceutical	$0.26	1.22%	N/A	32.91%	N/A
DSNKY Daiichi Sankyo	$0.29	1.15%	N/A	28.16%	N/A
SDZNY Sandoz Group	$0.44	0.74%	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.30%	N/A	34.42%	14 Years

Latest SDZNY, CHGCY, ZTS, and DSNKY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHGCY Chugai Pharmaceutical	N/A	6.04	5.16
DSNKY Daiichi Sankyo	0.06	2.53	1.85
SDZNY Sandoz Group	0.57	1.24	0.79
ZTS Zoetis	1.05	1.76	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHGCY Chugai Pharmaceutical	0.01%
DSNKY Daiichi Sankyo	N/A
SDZNY Sandoz Group	0.06%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CHGCY Chugai Pharmaceutical	N/A
DSNKY Daiichi Sankyo	N/A
SDZNY Sandoz Group	N/A
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHGCY Chugai Pharmaceutical	7,778	3.29 billion	N/A	Not Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable
ZTS Zoetis	13,800	443.18 million	442.39 million	Optionable

SDZNY, CHGCY, ZTS, and DSNKY Headlines

Recent News About These Companies

David Rolfe's Strategic Moves: Zoetis Inc. Takes Center Stage with 3.63% Portfolio Impact

August 15 at 10:28 AM | gurufocus.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $18.41 Million Holdings in Zoetis Inc. (NYSE:ZTS)

August 15 at 7:31 AM | marketbeat.com

Gulf International Bank UK Ltd Sells 8,454 Shares of Zoetis Inc. (NYSE:ZTS)

August 15 at 6:24 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Position Boosted by National Pension Service

August 15 at 6:10 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Russell Investments Group Ltd.

August 15 at 5:55 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Public Sector Pension Investment Board

August 15 at 5:17 AM | marketbeat.com

5 Revealing Analyst Questions From Zoetis’s Q2 Earnings Call

August 14 at 10:22 AM | finance.yahoo.com

Neuberger Berman Group LLC Sells 119,616 Shares of Zoetis Inc. (NYSE:ZTS)

August 14 at 7:52 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Tokio Marine Asset Management Co. Ltd.

August 14 at 7:16 AM | marketbeat.com

S Bank Fund Management Ltd Buys New Shares in Zoetis Inc. (NYSE:ZTS)

August 14 at 6:59 AM | marketbeat.com

Rossmore Private Capital Sells 1,780 Shares of Zoetis Inc. (NYSE:ZTS)

August 14 at 5:48 AM | marketbeat.com

ZTS Q2 Deep Dive: Market Questions Librela Outlook Amid Double-Digit Growth in Core Franchises

August 13 at 9:06 AM | finance.yahoo.com

Prudential PLC Acquires 13,718 Shares of Zoetis Inc. (NYSE:ZTS)

August 13 at 7:02 AM | marketbeat.com

Resona Asset Management Co. Ltd. Increases Holdings in Zoetis Inc. (NYSE:ZTS)

August 13 at 6:54 AM | marketbeat.com

Rathbones Group PLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

August 13 at 6:53 AM | marketbeat.com

Piper Sandler Keeps Their Buy Rating on Zoetis (ZTS)

August 12, 2025 | theglobeandmail.com

Capital Planning Advisors LLC Sells 2,552 Shares of Zoetis Inc. (NYSE:ZTS)

August 12, 2025 | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Gouws Capital LLC

August 12, 2025 | marketbeat.com

Virtu Financial LLC Decreases Stock Position in Zoetis Inc. (NYSE:ZTS)

August 12, 2025 | marketbeat.com

Invesco Ltd. Acquires 44,977 Shares of Zoetis Inc. (NYSE:ZTS)

August 12, 2025 | marketbeat.com

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

August 11, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDZNY, CHGCY, ZTS, and DSNKY Company Descriptions

Chugai Pharmaceutical OTCMKTS:CHGCY

$21.28 +0.49 (+2.36%)

As of 08/15/2025 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Daiichi Sankyo OTCMKTS:DSNKY

$25.11 +0.70 (+2.87%)

As of 08/15/2025 04:00 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Sandoz Group OTCMKTS:SDZNY

$59.32 +0.71 (+1.21%)

As of 08/15/2025 03:58 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Zoetis NYSE:ZTS

$154.15 +1.09 (+0.71%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$153.07 -1.08 (-0.70%)

As of 08/15/2025 07:52 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time